BriaCell Therapeutics has started dosing patients in a Phase I/IIa trial to evaluate Bria-IMT in combination with pembrolizumab (Keytruda) or ipilimumab (Yervoy) for the treatment of advanced breast cancer.

Keytruda is manufactured by Merck and Yervoy is developed by Bristol-Myers Squibb Company.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Both drugs are immune checkpoint inhibitors designed to overcome immune suppression in cancer patients.

As part of the open-label, non-randomised, parallel assignment, Phase I/IIa trial, BriaCell is expected to enrol 40 subjects.

During the trial, the combination of Keytruda and Bria-IMT will be provided to patients with expression of programmed death-ligand 1 (PD-L1) or PD-L2.

Patients without expression of PD-L1 or PD-L2 will receive the combination of Bria-IMT and Yervoy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“BriaCell is committed to exploring additional ways to address the unmet needs of the advanced breast cancer community.”

The trial’s primary endpoint is safety, while the secondary endpoints include assessment of tumour response, immune responses, tumour characteristics, quality of life (QOL), among others.

BriaCell Therapeutics president and CEO Dr Bill Williams said: “We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with Keytruda or Yervoy.

“BriaCell is committed to exploring additional ways to address the unmet needs of the advanced breast cancer community.”

Bria-IMT is BriaCell’s lead clinical candidate that is designed as a breast cancer cell line engineered to produce an immune-activating factor (GM-CSF).

Last month, BriaCell reported positive proof of concept data from a Phase I/IIa study evaluating Bria-IMT in advanced breast cancer.

The results showed improved levels of safety and efficacy of Bria-IMT in the enrolled patients.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now